Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end-products: comparison with aminoguanidine.

Booth AA, Khalifah RG, Hudson BG
Biochem Biophys Res Commun. 1996 220 (1): 113-9

PMID: 8602828 · DOI:10.1006/bbrc.1996.0366

Nonenzymatic glycation of proteins by glucose leading to the formation of toxic and immunogenic advanced glycation end products (AGEs) may be a major contributor to the pathological manifestations of diabetes mellitus, aging, and, possibly, neurodegenerative diseases such as Alzheimer's. We tested the in vitro inhibition of antigenic AGE formation on bovine serum albumin, ribonuclease A, and human hemoglobin by various vitamin B1 and B6 derivatives. Among the inhibitors, pyridoxamine and thiamine pyrophosphate potently inhibited AGE formation and were more effective than aminoguanidine, suggesting that these two compounds may have novel therapeutic potential in preventing vascular complications of diabetes. An unexpected finding was that aminoguanidine inhibited the late kinetic stages of glycation much more weakly than the early phase.

MeSH Terms (18)

Animals Antigens Cattle Diabetes Complications Diabetes Mellitus Enzyme Inhibitors Glycation End Products, Advanced Glycosylation Guanidines Humans In Vitro Techniques Male Methemoglobin Pyridoxamine Rabbits Ribonuclease, Pancreatic Serum Albumin, Bovine Thiamine Pyrophosphate

Connections (2)

This publication is referenced by other Labnodes entities: